PHENOS · PHENOtyping targeted single-cell via integrated digital microfluidics and optoelectronic tweezerS
„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“
- Период
- 2027-07-10 → 2030-07-09
- Финансиране от ЕС
- 317 923 €
- Участници
- 2
- Схема
- HORIZON-TMA-MSCA-PF-GF
Линиите свързват координатора с партньорите.
Накратко на български
Хибридна платформа от микрофлуидика и светлинни пинцети ще анализира отделни ракови клетки, за да разбере различията между тях. Това помага за разгадаване на разнообразието в туморите, което може да насочи избора на персонализирано лечение за пациентите.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Цел на проекта
Cellular populations are rich in diversity, and understanding this heterogeneity at the single-cell level is crucial in oncology, where specific subpopulations can drive tumour progression, metastasis, and therapy resistance. PHENOS (“PHENOtyping targeted single-cell via integrated digital microfluidics and optoelectronic tweezerS”) addresses this challenge by introducing the first hybrid platform for targeted single-cell analysis and manipulation. The system combines digital microfluidics (DMF) for precise liquid handling, aptamer-mediated cell surface functionalization for molecular targeting, optoelectronic tweezers (OET) for non-invasive manipulation, and advanced data analysis algorithms for high-resolution phenotypic profiling. The project is structured in four phases: (1) design and validation of DMF and OET devices, (2) integration into a hybrid opto-microfluidic platform, (3) targeted cell functionalization and longitudinal phenotyping through time-lapse imaging, and (4) development of machine learning and deep learning algorithms for classification and phenotypic stratification. Through a comprehensive and synergistic training programme bridging engineering, biology, chemistry, and computational science, PHENOS will: (1) establish a dynamic, high-precision workflow for single-cell measurement and sorting, and (2) enhance OET sensitivity and specificity, achieving ≥95% classification accuracy, in independent experiments, with an expected 20% gain from aptamer targeting. By overcoming current limitations, PHENOS will establish a novel framework for decoding cellular heterogeneity in cancer with a decision-making process, guiding personalised treatments and improving patient outcomes, while providing me a unique multidisciplinary environment to build scientific independence and long-term leadership.
Оригинален текст от CORDIS (на английски).
Участници
Връзки
Данни: CORDIS, © Европейски съюз